Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia

Oman Medical Journal

Volumn 28, Issue 2, 2013, Pages 121-124

  Al Khabori, Murtadha ^a   Bhandari, Sunil ^b   Al Huneini, Mohammed ^a   Al Farsi, Khalil ^a   Panjwani, Vinodh ^a   Daar, Shahina ^c  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^c SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Chelator; Kidney function; Thalassemia; Toxicity

Indexed keywords

CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADULT; AGRANULOCYTOSIS; ARTICLE; BETA THALASSEMIA; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEPATITIS C; HUMAN; INCIDENCE; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; THALASSEMIA MAJOR;

EID: 84875916077     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2013.31     Document Type: Article

References (11)

1. Olivieri NF. The beta-thalassemias. N Engl J Med 1999 Jul;341(2):99-109.
2. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005 Sep;353(11):1135-1146.
3. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009 May;20(5):1069-1077.
4. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010 Jun;375(9731):2073-2081.
5. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009 Aug;20(8):1813-1821.
6. Kuan Y, Hossain M, Surman J, El Nahas AM, Haylor J. GFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease. Nephrol Dial Transplant 2005 Nov;20(11):2394-2401.
7. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006 May;107(9):3455-3462.
8. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011 Jul;118(4):884-893.
9. Mula-Abed WA, Al-Hashmi HS, Al-Muslahi MN. Indicators of Renal Glomerular and Tubular Functions in Patients with Beta-Thalassaemia Major: A cross sectional study at the Royal Hospital, Oman. Sultan Qaboos Univ Med J 2011 Feb;11(1):69-76.
10. Mula-Abed WA, Al Hashmi H, Al Muslahi M, Al Muslahi H, Al Lamki M. Prevalence of endocrinopathies in patients with Beta-thalassaemia major-a cross-sectional study in oman. Oman Med J 2008 Oct;23(4):257-262.
11. Tanji K, Imaizumi T, Matsumiya T, Itaya H, Fujimoto K, Cui X, et al. Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochim Biophys Acta 2001 Feb;1530(2-3):227-235.